Logo image of AKBM.OL

AKER BIOMARINE ASA (AKBM.OL) Stock Fundamental Analysis

Europe - Euronext Oslo - OSL:AKBM - NO0010886625 - Common Stock

99.6 NOK
+2.3 (+2.36%)
Last: 1/9/2026, 4:11:59 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to AKBM. AKBM was compared to 60 industry peers in the Food Products industry. AKBM has a medium profitability rating, but doesn't score so well on its financial health evaluation. AKBM has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

AKBM had positive earnings in the past year.
AKBM had a positive operating cash flow in the past year.
In multiple years AKBM reported negative net income over the last 5 years.
AKBM had a positive operating cash flow in 4 of the past 5 years.
AKBM.OL Yearly Net Income VS EBIT VS OCF VS FCFAKBM.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

1.2 Ratios

AKBM's Return On Assets of 44.73% is amongst the best of the industry. AKBM outperforms 100.00% of its industry peers.
AKBM has a better Return On Equity (115.79%) than 100.00% of its industry peers.
AKBM's Return On Invested Capital of 1.30% is on the low side compared to the rest of the industry. AKBM is outperformed by 71.67% of its industry peers.
Industry RankSector Rank
ROA 44.73%
ROE 115.79%
ROIC 1.3%
ROA(3y)16.04%
ROA(5y)9.26%
ROE(3y)36.62%
ROE(5y)21.25%
ROIC(3y)N/A
ROIC(5y)N/A
AKBM.OL Yearly ROA, ROE, ROICAKBM.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80 100

1.3 Margins

AKBM has a better Profit Margin (67.04%) than 100.00% of its industry peers.
AKBM's Operating Margin of 2.05% is on the low side compared to the rest of the industry. AKBM is outperformed by 68.33% of its industry peers.
AKBM has a Gross Margin of 43.26%. This is in the better half of the industry: AKBM outperforms 63.33% of its industry peers.
In the last couple of years the Gross Margin of AKBM has remained more or less at the same level.
Industry RankSector Rank
OM 2.05%
PM (TTM) 67.04%
GM 43.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.45%
GM growth 5Y0.36%
AKBM.OL Yearly Profit, Operating, Gross MarginsAKBM.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so AKBM is destroying value.
The number of shares outstanding for AKBM remains at a similar level compared to 1 year ago.
The number of shares outstanding for AKBM remains at a similar level compared to 5 years ago.
AKBM has a better debt/assets ratio than last year.
AKBM.OL Yearly Shares OutstandingAKBM.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AKBM.OL Yearly Total Debt VS Total AssetsAKBM.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

AKBM has an Altman-Z score of 1.70. This is a bad value and indicates that AKBM is not financially healthy and even has some risk of bankruptcy.
AKBM has a Altman-Z score of 1.70. This is in the lower half of the industry: AKBM underperforms 65.00% of its industry peers.
AKBM has a Debt/Equity ratio of 1.06. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of AKBM (1.06) is worse than 71.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF N/A
Altman-Z 1.7
ROIC/WACC0.15
WACC8.52%
AKBM.OL Yearly LT Debt VS Equity VS FCFAKBM.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

AKBM has a Current Ratio of 2.62. This indicates that AKBM is financially healthy and has no problem in meeting its short term obligations.
AKBM has a Current ratio of 2.62. This is amongst the best in the industry. AKBM outperforms 86.67% of its industry peers.
AKBM has a Quick Ratio of 1.25. This is a normal value and indicates that AKBM is financially healthy and should not expect problems in meeting its short term obligations.
AKBM's Quick ratio of 1.25 is fine compared to the rest of the industry. AKBM outperforms 76.67% of its industry peers.
Industry RankSector Rank
Current Ratio 2.62
Quick Ratio 1.25
AKBM.OL Yearly Current Assets VS Current LiabilitesAKBM.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

5

3. Growth

3.1 Past

AKBM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15747.24%, which is quite impressive.
AKBM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.34%.
The Revenue has been decreasing by -4.17% on average over the past years.
EPS 1Y (TTM)15747.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)-15.34%
Revenue growth 3Y-8.77%
Revenue growth 5Y-4.17%
Sales Q2Q%-41.17%

3.2 Future

The Earnings Per Share is expected to grow by 96.03% on average over the next years. This is a very strong growth
Based on estimates for the next years, AKBM will show a very strong growth in Revenue. The Revenue will grow by 20.59% on average per year.
EPS Next Y70%
EPS Next 2Y117.56%
EPS Next 3Y96.03%
EPS Next 5YN/A
Revenue Next Year-14.74%
Revenue Next 2Y-1.39%
Revenue Next 3Y2.27%
Revenue Next 5Y20.59%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AKBM.OL Yearly Revenue VS EstimatesAKBM.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
AKBM.OL Yearly EPS VS EstimatesAKBM.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 0.1 -0.1 0.2 0.3

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 4.96, the valuation of AKBM can be described as very cheap.
AKBM's Price/Earnings ratio is rather cheap when compared to the industry. AKBM is cheaper than 96.67% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.00, AKBM is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 40.84, the valuation of AKBM can be described as expensive.
Based on the Price/Forward Earnings ratio, AKBM is valued a bit more expensive than 70.00% of the companies in the same industry.
AKBM's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.70.
Industry RankSector Rank
PE 4.96
Fwd PE 40.84
AKBM.OL Price Earnings VS Forward Price EarningsAKBM.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AKBM is valued a bit more expensive than the industry average as 70.00% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 22.26
AKBM.OL Per share dataAKBM.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

AKBM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AKBM's earnings are expected to grow with 96.03% in the coming years.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y117.56%
EPS Next 3Y96.03%

0

5. Dividend

5.1 Amount

No dividends for AKBM!.
Industry RankSector Rank
Dividend Yield 0%

AKER BIOMARINE ASA

OSL:AKBM (1/9/2026, 4:11:59 PM)

99.6

+2.3 (+2.36%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)10-31 2025-10-31
Earnings (Next)02-12 2026-02-12/amc
Inst Owners5.57%
Inst Owner ChangeN/A
Ins Owners6.14%
Ins Owner ChangeN/A
Market Cap8.73B
Revenue(TTM)258.20M
Net Income(TTM)173.10M
Analysts77.78
Price Target86.7 (-12.95%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend42.9
Dividend Growth(5Y)N/A
DP215.6%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)6.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.59%
Valuation
Industry RankSector Rank
PE 4.96
Fwd PE 40.84
P/S 3.35
P/FCF N/A
P/OCF 210.91
P/B 5.78
P/tB 31.56
EV/EBITDA 22.26
EPS(TTM)20.07
EY20.15%
EPS(NY)2.44
Fwd EY2.45%
FCF(TTM)-1.75
FCFYN/A
OCF(TTM)0.47
OCFY0.47%
SpS29.74
BVpS17.22
TBVpS3.16
PEG (NY)0.07
PEG (5Y)N/A
Graham Number88.18
Profitability
Industry RankSector Rank
ROA 44.73%
ROE 115.79%
ROCE 1.69%
ROIC 1.3%
ROICexc 1.39%
ROICexgc 2.38%
OM 2.05%
PM (TTM) 67.04%
GM 43.26%
FCFM N/A
ROA(3y)16.04%
ROA(5y)9.26%
ROE(3y)36.62%
ROE(5y)21.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.45%
GM growth 5Y0.36%
F-Score5
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF N/A
Debt/EBITDA 3.5
Cap/Depr 48.25%
Cap/Sales 7.47%
Interest Coverage 0.39
Cash Conversion 9.05%
Profit Quality N/A
Current Ratio 2.62
Quick Ratio 1.25
Altman-Z 1.7
F-Score5
WACC8.52%
ROIC/WACC0.15
Cap/Depr(3y)77.43%
Cap/Depr(5y)88.04%
Cap/Sales(3y)14.31%
Cap/Sales(5y)16.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15747.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y70%
EPS Next 2Y117.56%
EPS Next 3Y96.03%
EPS Next 5YN/A
Revenue 1Y (TTM)-15.34%
Revenue growth 3Y-8.77%
Revenue growth 5Y-4.17%
Sales Q2Q%-41.17%
Revenue Next Year-14.74%
Revenue Next 2Y-1.39%
Revenue Next 3Y2.27%
Revenue Next 5Y20.59%
EBIT growth 1Y60.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year170.83%
EBIT Next 3Y67.11%
EBIT Next 5YN/A
FCF growth 1Y62.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-14.58%
OCF growth 3Y155.79%
OCF growth 5Y-0.17%

AKER BIOMARINE ASA / AKBM.OL FAQ

Can you provide the ChartMill fundamental rating for AKER BIOMARINE ASA?

ChartMill assigns a fundamental rating of 4 / 10 to AKBM.OL.


Can you provide the valuation status for AKER BIOMARINE ASA?

ChartMill assigns a valuation rating of 4 / 10 to AKER BIOMARINE ASA (AKBM.OL). This can be considered as Fairly Valued.


Can you provide the profitability details for AKER BIOMARINE ASA?

AKER BIOMARINE ASA (AKBM.OL) has a profitability rating of 4 / 10.


How financially healthy is AKER BIOMARINE ASA?

The financial health rating of AKER BIOMARINE ASA (AKBM.OL) is 3 / 10.


What is the earnings growth outlook for AKER BIOMARINE ASA?

The Earnings per Share (EPS) of AKER BIOMARINE ASA (AKBM.OL) is expected to grow by 70% in the next year.